Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Travere Therapeutics offers rare kidney disease treatments with FDA-approved Filspari. Check out why I deem TVTX stock as a ...
Strong Buy Rating for Travere Therapeutics Backed by Filspari’s Market Potential and Full FDA Approval
Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) and keeping the price ...
FiercePharma9d
Travere pumps brakes on late-stage enzyme replacement therapy study, citing production scale-up problems
Shortly after winning full FDA approval for its rare kidney disease drug Filspari, San Diego’s Travere Therapeutics has run ...
GlobalData on MSN29d
After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN
The US Food and Drug Administration (FDA) has converted the accelerated approval for Travere Therapeutics’ Filspari ...
MedCity News1mon
Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas
The Travere drug, Filspari, treats immunoglobulin A nephropathy (IgAN), a disease in which a patient’s immune system produces excessive amounts of antibodies that damage the kidney. Filspari’s ...
Business Wire1mon
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function ...
FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on ...
Monthly Prescribing Reference1mon
Filspari Approved to Slow Kidney Function Decline in IgA Nephropathy
The final analysis showed treatment with sparsentan reduced the rate of decline in kidney function vs irbesartan. The Food and Drug Administration (FDA) has granted full approval to Filspari ...
MarketWatch1mon
Travere Therapeutics Shares Rise on Full FDA Nod for Kidney Drug
Shares of Travere Therapeutics moved higher after the biopharmaceutical company said it won full Food and Drug Administration approval of its kidney-disease drug Filspari. Travere shares were ...
BioWorld1mon
Travere’s Filspari safari bags full FDA nod in IgAN; REMS next
With full approval from the U.S. FDA in hand for Travere Therapeutics Inc.’s Filspari (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) who are at risk of ...